QURE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Uniqure NV (QURE) is not a good buy at this time for a beginner investor with a long-term strategy. The stock faces significant regulatory hurdles, negative sentiment from analysts, and weak financial performance. Despite a slight revenue increase, the company's net income and EPS have significantly declined. The technical indicators also suggest bearish momentum. Given the lack of positive catalysts and the uncertain future of its key drug pipeline, holding off on this investment is the prudent choice.
The technical indicators for QURE are bearish. The MACD histogram is negative and contracting, RSI is neutral but leaning towards oversold territory, and the moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 10.633, with resistance levels at 17.009 and 23.384.
The company's gross margin increased to 92.19%, up 4.59% YoY, which is a positive sign for operational efficiency.
The FDA's requirement for a new sham surgery-controlled Phase 3 trial for AMT-130 in Huntington's disease is a significant setback. Analysts have downgraded the stock and drastically reduced price targets. Additionally, a class action lawsuit has been filed against the company, further damaging investor sentiment.
In Q4 2025, revenue increased by 6.65% YoY to $5,568,000. However, net income dropped by 49.38% YoY to -$37,086,000, and EPS fell by 60.67% YoY to -0.59, indicating worsening profitability.
Analysts have overwhelmingly downgraded the stock, with price targets significantly reduced. The consensus is that the regulatory hurdles for AMT-130 will delay approval by several years, diminishing investor confidence in the company's pipeline and future growth prospects.
